Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study

To compare cardiovascular and mortality risks in elderly patients treated with varenicline or bupropion for smoking cessation.

[1]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[2]  P. Gideon,et al.  An algorithm to identify incident myocardial infarction using Medicaid data , 2009, Pharmacoepidemiology and drug safety.

[3]  W. Longstreth,et al.  Validating Administrative Data in Stroke Research , 2002, Stroke.

[4]  F. Ivy Carroll,et al.  Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors , 2006, Molecular Pharmacology.

[5]  Kenneth W Lin,et al.  Nicotine receptor partial agonists for smoking cessation. , 2011, American family physician.

[6]  Jordi Castellsague,et al.  Positive predictive value of ICD‐9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database , 2008, Pharmacoepidemiology and drug safety.

[7]  S. Normand,et al.  Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database , 1999, Journal of General Internal Medicine.

[8]  H. Svanström,et al.  Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study , 2012, BMJ : British Medical Journal.

[9]  J. Prochaska,et al.  Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[10]  Jordi Castellsague,et al.  Validation of ICD‐9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data , 2008, Pharmacoepidemiology and drug safety.

[11]  이재복.  의사 간호사 communication , 2011 .

[12]  A R Levy,et al.  Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. , 1999, The Canadian journal of cardiology.

[13]  C. Furberg,et al.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.

[14]  Michael D. Hill,et al.  Coding of Stroke and Stroke Risk Factors Using International Classification of Diseases, Revisions 9 and 10 , 2005, Stroke.

[15]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[16]  Daniel Polsky,et al.  Coronary revascularization trends in the United States, 2001-2008. , 2011, JAMA.

[17]  P. Austin,et al.  Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding , 2005, BMJ : British Medical Journal.

[18]  Terry F. Pechacek,et al.  Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004. , 2008, MMWR. Morbidity and mortality weekly report.

[19]  J. Foulds.  The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline , 2006, International journal of clinical practice.

[20]  Nicholas Smith,et al.  Smoking Status and Risk for Recurrent Coronary Events after Myocardial Infarction , 2002, Annals of Internal Medicine.

[21]  M. Harrison‐Woolrych,et al.  Utilization of the smoking cessation medicine varenicline: an intensive post‐marketing study in New Zealand , 2010, Pharmacoepidemiology and drug safety.

[22]  F. Carroll,et al.  Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. , 2006, Molecular pharmacology.

[23]  Sebastian Schneeweiss,et al.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.

[24]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[25]  J. Murabito,et al.  Depressive Symptoms, Coronary Heart Disease, and Overall Mortality in the Framingham Heart Study , 2005, Psychosomatic medicine.

[26]  D. Rubin,et al.  Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .

[27]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[28]  Mark E. Hill,et al.  The Social Security Administration's Death Master File: the completeness of death reporting at older ages. , 2001, Social security bulletin.

[29]  W. Kop,et al.  Association between depression and mortality in older adults: the Cardiovascular Health Study. , 2000, Archives of internal medicine.

[30]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[31]  Y. Matsuyama,et al.  Marginal Structural Models as a Tool for Standardization , 2003, Epidemiology.

[32]  Peter C Austin,et al.  A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. , 2002, American heart journal.

[33]  J. Ebbert,et al.  Varenicline for tobacco dependence. , 2008, The New England journal of medicine.

[34]  J. Pearl,et al.  Confounding and Collapsibility in Causal Inference , 1999 .

[35]  Louette R. Johnson Lutjens.  Research , 2006 .

[36]  S. Yusuf,et al.  Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study , 2006, The Lancet.